伊诺国际学术专家来华讲座议程大咖面对面
了解前沿领域和行业动态，启发科研思路，激发学术灵感，伊诺国际科研2019年最后一波国际专家来华讲座，大咖面对面，为各省市各大医院进行巡回研讨前沿课题。
专家信息
姓名：Gautam Sethi
国家：新加坡
最高学历：博士
职称：教授
所在学校：National University of Singapore, Department of Pharmacology, Yong Loo Lin School of Medicine (新加坡国立大学)
学校影响力：2019年5月，新加坡国立大学在2019年英国泰晤士高等教育亚洲大学排名中位列第二，2019年6月19日，2020 QS世界大学排名发布，新加坡国立大学排名第11位。
研究领域
致癌物和炎症因子调控致癌转录因子的机制。
研究及鉴定可以抑制转录因子的激活的新的药理化合物。
原位/转基因和异种移植小鼠肿瘤模型的建立和表征。
专家学术影响力
Dr. Gautam Sethi 共发表331篇论文，总引用数 23697，H-index (Scopus)为74，i10-index为242(来自Google Scholar)，Dr. Gautam Sethi博士毕业于Banaras Hindu University，之后前往美国Anderson Cancer Centre做博士后工作，现任职新加坡国立大学，Yong Loo Lin School of Medicine学院教授。主要研究领域为：致癌物和炎症因子调控致癌转录因子的机制，研究及鉴定可以抑制转录因子的激活的新的药理化合物，原位/转基因和异种移植小鼠肿瘤模型的建立和表征，发表高分值论文百篇以上。
注：H-index指数在一定程度上可以评价研究学者的学术成就和影响力。施一公，曾任清华大学教授，中国科学院院士、结构生物学家，其H-index (Scopus) 为87。陈竺，分子生物学家，中国科学院院士、第三世界科学院院士、美国国家科学院外籍院士、法国科学院外籍院士，上海第二医科大学附属瑞金医院教授，其H-index (Scopus) 为77。
报告题目
植物化合物对lncRNA在癌症和其他慢性疾病(类风湿性关节炎，骨关节炎和非酒精性脂肪肝)中的调节和治疗作用机制The Regulatory and Therapeutic Mechanisms of Phytochemicals for lncRNA in Cancer and Other Chronic Diseases
学术代表作
1. Dharambir Kashyap, Hardeep Singh Tuli, Mukerrem Betul Yerer, Ajay Sharma, Katrin Sak, Saumya Srivastava, Anjana Pandey, Vivek Kumar Garg, Gautam Sethi, Anupam Bishayee, Natural product-based nanoformulations for cancer therapy: Opportunities and challenges, Seminars in Cancer Biology, 2019 In press. (IF=9.7)
1. RS Varughese, WST Lam, AAH Marican, SH Viganeshwari, AS Bhave, Gautam Sethi, et al. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential. Cancer 125 (11), 2019, 1789-1798. (IF=6.1)
3. CE Halim, SL Xinjing, L Fan, JB Vitarbo, F Arfuso, CH Tan, AS Narula, Gautam Sethi, et. al. Anti-cancer effects of oxymatrine are mediated through multiple molecularmechanism (s) in tumor models. Pharmacological research, 147, September 2019, 104327 (IF=5.6).
4. S Mishra, SS Verma, V Rai, N Awasthee, S Chava, KM Hui, AP Kumar, Gautam Sethi, et al. Long non-coding RNAs are emerging targets of phytochemicals for cancerand other chronic diseases. Cellular and Molecular Life Sciences 76 (10), 2019, 1947-1966. (IF=7.0).
5. L Arora, CSH Tan, RM Sobota, G Sethi. Identification of molecular targets of Tris DBA [Tris (dibenzylideneacetone) dipalladium (0)] for cancer therapy. Cancer Research 79 (13 Supplement), 2019, 1240-1240. (IF=8.4)
6. Chai EZ, Shanmugam MK, Arfuso F, Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC, Ahn KS, Hui KM, Sethi G. Targeting transcription factor STAT3 for cancer prevention and therapy. (2015). Pharmacol Ther. 2016 Jun;162:86-97. (IF=9.7).
7. Zhang J, Ahn KS, Kim C, Shanmugam MK, Siveen KS, Arfuso F, Samy RP, Deivasigamani A, Lim LH, Wang L, Goh BC, Kumar AP, Hui KM, Sethi G. Nimbolide-induced oxidative stress abrogates STAT3 signaling cascade and inhibits tumor growth in transgenic adenocarcinoma of mouse prostate model. (2015). Antioxid Redox Signal. 2016 Apr 10;24(11):575-89. (IF= 7.4).
8. Li F, Shanmugam MK, Siveen KS, Wang F, Ong TH, Loo SY, Swamy MM, Mandal S, Kumar AP, Goh BC, Kundu T, Ahn KS, Wang LZ, Hui KM, Sethi G. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. (2015). Oncotarget. 6: 5147-5163. (IF=6.6).
9. Dai X, Ahn KS, Kim C, Siveen KS, Ong TH, Shanmugam MK, Li F, Shi J, Kumar AP, Wang LZ, Goh BC, Magae J, Hui KM, Sethi G. Ascochlorin, an isoprenoid antibiotic inhibits growth and invasion of hepatocellular carcinoma by targeting STAT3 signaling cascade through the induction of PIAS3. (2015). Mol Oncol. 9:818-833. (IF=5.7).
10. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP, Tergaonkar V. DEAD-box Helicase DP103 Defines the Metastatic Potential of Human Breast Cancers. (2014). J Clin Invest. 124: 3807- 3824 (IF=13.2).
11. Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BK, Sethi G*, Bishayee A. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. (2014). Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1845: 136-154 (IF= 7.5). *Co-corresponding author.
12. Siveen KS, Ahn KS, Ong TH, Shanmugam MK, Li F, Yap WN, Kumar AP, Fong CW, Tergaonkar V, Hui KM, Sethi G. γ-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. (2014) Oncotarget. 5: 1897-1911. (IF=6.6).
13. Subramaniam A, Shanmugam MK, Perumal E, Li F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, Hui KM, Sethi G. Potential Role of Signal Transducer and Activator of Transcription (STAT)3 Signaling Pathway in Inflammation, Survival, Proliferation and Invasion of Hepatocellular Carcinoma. (2013). Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1835: 46-60 (IF=7.5).
14. Manu KA, Shanmugam M, Ramachandran L, Li F, Fong CW, Kumar AP, Tan P, Sethi G. First evidence that g-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kB pathway. (2012). Clin Cancer Res. 18: 2220-2229 (IF= 8.7).
